FOLFIRI + Bevacizumab ± Pelareorep for Colorectal Cancer

This trial tests a new combination of cancer treatments to determine its effectiveness for individuals with metastatic colorectal cancer and a specific RAS mutation. Researchers aim to discover whether adding pelareorep, an experimental treatment, to the standard drugs FOLFIRI and bevacizumab can enhance patient outcomes. Suitable candidates for this trial have metastatic colorectal cancer, have not responded to a specific type of chemotherapy, and are not eligible for surgery or radiation. As a Phase 2 trial, this research focuses on assessing the treatment's efficacy in an initial, smaller group, providing an opportunity to potentially benefit from new treatment options.

The trial does not specify if you need to stop taking your current medications. However, you cannot participate if you are receiving immunosuppressive or myelosuppressive medications, or if you have ongoing side effects from previous cancer treatments.

Research has shown that combining bevacizumab with FOLFIRI chemotherapy is generally well-tolerated by patients. Studies have found that this combination maintains a consistent safety record, with no unexpected side effects reported. Additionally, one study found that patients using this combination lived for a median of 24.4 months, suggesting it may extend life expectancy.

Pelareorep, another drug tested in one part of the trial, has shown promising results in other studies. Early data suggest it might improve survival in patients with a specific type of colorectal cancer. Although detailed safety information for pelareorep remains limited, its recent FDA Fast Track designation indicates potential benefits and acceptable safety in early trials.

Researchers are excited about these treatments because they explore the combination of traditional chemotherapy with innovative viral therapy. Unlike standard treatments for colorectal cancer, which typically involve drugs like FOLFIRI and bevacizumab, this trial adds pelareorep, an oncolytic virus that targets and destroys cancer cells while sparing healthy ones. This unique mechanism could enhance the effectiveness of existing therapies and potentially improve patient outcomes by boosting the immune response against cancer. By combining these treatments, researchers hope to offer a more powerful and targeted approach to fighting colorectal cancer.

This trial will compare two treatment approaches for colorectal cancer. One group will receive FOLFIRI and bevacizumab, while the other will receive FOLFIRI, bevacizumab, and Pelareorep. Research has shown that adding Pelareorep to FOLFIRI and bevacizumab yields promising results. Specifically, about one-third of patients experienced tumor shrinkage with this combination, lasting an average of 19.5 months. This outcome is significantly better than the usual response rates for standard treatments, which typically range from 6% to 11%. Additionally, earlier studies found that patients lived a median of 27 months with this combination, compared to 11.2 months with standard care. These findings suggest that the Pelareorep combination could be a more effective option for patients with certain genetic types of colorectal cancer.¹²⁶⁷⁸